Sign In
Buy DSNKY
$15.23
-0.94 (-5.81%)
At Close: Jun 03, 2026
Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript
01:40pm, Friday, 01'st Nov 2024
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET Company Participants Hiroyuki Okuzawa - Representative Director, President & Chief Operating
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
07:00am, Wednesday, 18'th Sep 2024
Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2-positi
Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial
06:11am, Tuesday, 17'th Sep 2024
Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease
11:00am, Saturday, 31'st Aug 2024
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining
Daiichi Sankyo Company, Limited (DSKYF) Q1 2024 Earnings Call Transcript
04:31pm, Monday, 05'th Aug 2024
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2024 Earnings Conference Call July 31, 2024 5:00 AM ET Company Participants Toshinori Agatsuma - Head of R&D Division Koji Ogawa - Head of Global Corpo
Daiichi Sankyo Opens New Affiliate for Oncology in Greece
06:06am, Wednesday, 10'th Jul 2024
ATHENS, Greece--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company's s
Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue
03:27am, Wednesday, 12'th Jun 2024
Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the p
RevolKa Signed Master Service Agreement with Daiichi Sankyo
09:00pm, Monday, 27'th May 2024
TOKYO--(BUSINESS WIRE)--RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, President and CEO) signed a master service ag
Perosphere Technologies Adds Dr. Michael Grosso to Advisory Board
09:03am, Monday, 20'th May 2024
DANBURY, Conn.--(BUSINESS WIRE)--Perosphere Technologies (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics, today ann
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
12:00am, Monday, 20'th May 2024
AstraZeneca (AZN Quick QuoteAZN - Free Report) announced its plans to spend $1.5 billion to build its first manufacturing facility in Singapore. Once built, it will be the company’s first facility t
Daiichi Sankyo shares growth projections, says its oncology business is a 'growth driver'
03:30am, Friday, 26'th Apr 2024
Hiroyuki Okuzawa, president and COO of the Japanese pharma company, discusses the company's results and growth projections.
Daiichi Sankyo Company, Limited (DSKYF) Q4 2023 Earnings Call Transcript
11:50pm, Thursday, 25'th Apr 2024
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q4 2023 Earnings Call Transcript April 25, 2024 2:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Hiroyuki Okuza
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
05:36pm, Friday, 05'th Apr 2024
The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.
Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Call Transcript
09:45pm, Thursday, 01'st Feb 2024
Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Call Transcript
Esperion resolves legal dispute with Daiichi Sankyo ahead of likely European drug approval
12:15pm, Wednesday, 03'rd Jan 2024
Esperion Therapeutics has reached a deal with Daiichi Sankyo to resolve a commercial dispute with an amendment to their ongoing collaboration. Daiichi Sankyo Europe GmbH, the company's European arm
